RE: Malachi17 Aug 2022 10:45
BOJO
Sure, ctDNA can be extracted from plasma. My issue is; what is the point of doing so when you can have the real thing rather that an epitope dependent fragment? The problem that Parsortix faces is, of course, that there is not a 100% recovery of CTCs on each occasion. It will depend on activity of the primary - shedding live tumour cells, and the presence of metastasis, etc,. - but, then, the same applies to extraction of fragments of tumour dna recovered from plasma. It perhaps depends on the same factors that govern the chances of ctc recovery by Parsortix.
But my point remains; what added value can fragments of dna add to clinical decison making?